Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Ries, D. Harkins, Martin Krapcho, A. Mariotto, B. Miller, E. Feuer, L. Clegg, M. Eisner, Marie-Josèphe Horner, N. Howlader, Matthew Hayat, B. Hankey, B. Edwards (2006)
SEER Cancer Statistics Review, 1975-2003
M. Guffey, JN Parker, WS Luckett, G. Gillespie, S. Meleth, R. Whitley, J. Markert (2007)
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumorsCancer Gene Therapy, 14
B. Huber, E. Austin, C. Richards, S. Davis, S. Good (1994)
Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.Proceedings of the National Academy of Sciences of the United States of America, 91 17
Micheéle Tiraby, C. Cazaux, M. Baron, D. Drocourt, J. Reynes, Geèrard Tiraby (1998)
Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine.FEMS microbiology letters, 167 1
G. Numico, E. Russi, R. Vitiello, R. Sorrentino, I. Colantonio, M. Cipolat, R. Taglianti, A. Pelissero, E. Fea, C. Granetto, G. Costanzo, M. Gasco, O. Garrone, M. Occelli, M. Merlano (2006)
Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule.International journal of radiation oncology, biology, physics, 66 3
J. Hu, R. Coffin, C. Davis, N. Graham, N. Groves, P. Guest, K. Harrington, N. James, C. Love, I. McNeish, L. Medley, A. Michael, C. Nutting, H. Pandha, C. Shorrock, J. Simpson, J. Steiner, N. Steven, D. Wright, R. Coombes (2006)
A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating FactorClinical Cancer Research, 12
A. Forastiere, H. Goepfert, M. Maor, T. Pajak, R. Weber, W. Morrison, B. Glisson, A. Trotti, J. Ridge, C. Chao, G. Peters, Ding‐Jen Lee, A. Leaf, J. Ensley, J. Cooper (2003)
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.The New England journal of medicine, 349 22
Fu (1997)
Radiation Therapy With 5-fluorouracil in Head and Neck Cancer.Seminars in radiation oncology, 7 4
G. Wolf, S. Fisher, W. Hong, Robert Hillman, M. Spaulding, G. Laramore, James Endicott, K. Mcclatchey, W. Henderson (1991)
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.The New England journal of medicine, 324 24
V. Preedy, R. Watson (2010)
European Organization for Research and Treatment of Cancer
J. Cooper, T. Pajak, A. Forastiere, J. Jacobs, B. Campbell, S. Saxman, J. Kish, Harold Kim, A. Cmelak, M. Rotman, M. Machtay, J. Ensley, K. Chao, C. Schultz, N. Lee, K. Fu (2004)
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.The New England journal of medicine, 350 19
B. deRubertis, Brendon Stiles, Amit Bhargava, N. Gusani, M. Hezel, M. D'Angelica, Yuman Fong (2007)
Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanismsCancer Gene Therapy, 14
A. Eisbruch, Teresa Lyden, C. Bradford, L. Dawson, M. Haxer, Amy Miller, T. Teknos, D. Chepeha, N. Hogikyan, J. Terrell, G. Wolf (2002)
Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer.International journal of radiation oncology, biology, physics, 53 1
H. Fukuda (2000)
European Organization for Research and Treatment of Cancer.Japanese journal of clinical oncology, 30 3
G. Simpson, Z. Han, Binlei Liu, Yibing Wang, G. Campbell, R. Coffin (2006)
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.Cancer research, 66 9
S. Malhotra, Teresa Kim, J. Zager, J. Bennett, M. Ebright, M. D'Angelica, Y. Fong (2007)
Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.Surgery, 141 4
J. Bernier, Christian Domenge, M. Ozsahin, K. Matuszewska, J. Lefebvre, R. Greiner, J. Giralt, P. Maingon, F. Rolland, M. Bolla, F. Cognetti, J. Bourhis, A. Kirkpatrick, M. Glabbeke (2004)
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.The New England journal of medicine, 350 19
A. Horwich, D. Sleijfer, S. Fosså, S. Kaye, R. Oliver, M. Cullen, G. Mead, R. Wit, P. Mulder, D. Dearnaley, P. Cook, R. Sylvester, S. Stenning (1997)
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 5
R. Wong, Mei‐ki Chan, Zhenkun Yu, Teresa Kim, A. Bhargava, B. Stiles, B. Horsburgh, J. Shah, R. Ghossein, Bhuvanesh Singh, Y. Fong (2004)
Effective Intravenous Therapy of Murine Pulmonary Metastases with an Oncolytic Herpes Virus Expressing Interleukin 12Clinical Cancer Research, 10
R. Wong, S. Patel, S. Kim, R. DeMatteo, S. Malhotra, J. Bennett, M. St‐Louis, J. Shah, P. Johnson, Y. Fong (2001)
Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.Human gene therapy, 12 3
Xinping Fu, L. Tao, A. Jin, R. Vile, M. Brenner, Xiaoliu Zhang (2003)
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.Molecular therapy : the journal of the American Society of Gene Therapy, 7 6
Waun Hong, R. Bromer (1983)
Chemotherapy in head and neck cancer.The New England journal of medicine, 308 2
J. Parker, G. Gillespie, Love Ce, S. Randall, R. Whitley, J. Markert (2000)
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.Proceedings of the National Academy of Sciences of the United States of America, 97 5
J. Bennett, S. Malhotra, R. Wong, K. Delman, J. Zager, M. St‐Louis, Paul Johnson, Y. Fong (2001)
Interleukin 12 Secretion Enhances Antitumor Efficacy of Oncolytic Herpes Simplex Viral Therapy for Colorectal CancerAnnals of Surgery, 233
R. Wong, Mei‐ki Chan, Zhenkun Yu, R. Ghossein, Ivan Ngai, P. Adusumilli, B. Stiles, J. Shah, Bhuvanesh Singh, Y. Fong (2004)
Angiogenesis Inhibition by an Oncolytic Herpes Virus Expressing Interleukin 12Clinical Cancer Research, 10
E. Galanis, A. Bateman, Kimberly Johnson, R. Díaz, C. James, R. Vile, Stephen Russell (2001)
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.Human gene therapy, 12 7
P Dirix, S Nuyts, V Vander Poorten, P Delaere, W Van den Bogaert (2008)
The influence of xerostomia after radiotherapy on quality of life: results of a questionnaire in head and neck cancer., 16
Jean Grem (1997)
Mechanisms of Action and Modulation of Fluorouracil.Seminars in radiation oncology, 7 4
P. Dirix, S. Nuyts, V. Poorten, P. Delaere, W. Bogaert (2008)
The influence of xerostomia after radiotherapy on quality of lifeSupportive Care in Cancer, 16
ORIGINAL ARTICLE Oncolysis Using Herpes Simplex Virus Type 1 Engineered to Express Cytosine Deaminase and a Fusogenic Glycoprotein for Head and Neck Squamous Cell Carcinoma Daniel L. Price, MD; Shu-Fu Lin, MD; Ziqun Han, MD; Guy Simpson, PhD; Robert S. Coffin, PhD; Joyce Wong, MD; Sen Li, BS; Yuman Fong, MD; Richard J. Wong, MD Objective: To determine if prodrug conversion of fluo- 3 of the 4 cell lines. Fluorocytosine did not enhance cy- GALV/CD rocytosine to fluorouracil by an engineered herpes vi- totoxicity induced by OncoVEX at a multiplicity GALV/CD rus, OncoVEX , enhances oncolytic therapy of head of infection of 0.1. However, for the least-sensitive SCC25 and neck squamous cell carcinoma. cell line, virus at a multiplicity of infection of 0.01 was cytotoxic to only 4% of cells after 6 days but was cyto- GALV/CD Design: We assessed the ability of OncoVEX and toxic to 35% of cells with fluorocytosine. GFP OncoVEX to infect, replicate within, and lyse 4 head and neck squamous cell carcinoma lines in vitro. The ef- GALV/CD Conclusions: OncoVEX efficiently infects, repli- GALV/CD fects of adding fluorocytosine with OncoVEX were cates within, and lyses head and neck squamous cell car- evaluated. cinoma at
JAMA Otolaryngology - Head & Neck Surgery – American Medical Association
Published: Feb 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.